Press Releases

09.12.2023

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

09.11.2023

Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

09.05.2023

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

08.30.2023

Pfizer Invites Public to View and Listen to Two Webcasts of Pfizer Discussions at Healthcare Conferences

08.30.2023

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union

08.24.2023

European Commission Approves Pfizer’s ABRYSVO™ to Help Protect Infants through Maternal Immunization and Older Adults from RSV

08.21.2023

U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Infants Through Active Immunization of Pregnant Individuals 32-36 Weeks of Gestational Age

08.14.2023

Pfizer’s ELREXFIO™ Receives U.S. FDA Accelerated Approval for Relapsed or Refractory Multiple Myeloma

08.01.2023

Pfizer Reports Second-Quarter 2023 Results

07.27.2023

Pfizer Announces Executive Leadership to Advance Oncology Research and Development Strategy

07.21.2023

Pfizer Announces Post-Tornado Relief Plans for Rocky Mount Community and Manufacturing Facility

07.19.2023

Pfizer Announces New England Journal of Medicine Publication on Group B Streptococcus (GBS) Maternal Vaccine Candidate